Tyruko (natalizumab-site), a natalizumab biosimilar, has been authorized by the FDA as…
Invimeds HealthSeptember 8, 2023
Latest Approval2
To become most Valued & Trusted partner for access to medicines. Driven by Knowledge and Services, InviMeds to become essential to its customers by providing access to most advanced treatment medicines and related services to help improve people’s quality of life.
© 2024 Invimeds. All Rights Reserved.